香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於開曼群島註冊成立的有限公司） （股份代號：2 3 8 9 ） 截 至 二 零 二 三 年 六 月 三 十 日 止 期 間 之 中 期 業 績 公 告 北京健康（控股）有限公司（「本公司」）董事會（「董事會」）謹此呈列本公司及其附 屬公司（統稱「本集團」）截至二零二三年六月三十日止六個月之未經審核中期 簡明綜合財務資料，連同二零二二年同期比較數字。中期簡明綜合財務資料未 經審核，惟已由本公司審核委員會審閱。 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 截至六月三十日止六個月 二零二三年 二零二二年 附註 千港元 千港元 （未經審核） （未經審核） 收入 4 78,038 91,807 ...

Share Capital and Ownership Structure - As of December 31, 2022, the public float capitalization was approximately HK$347,725,000, representing about 84.40% of the issued share capital of the company[10]. - Cosmic Stand International Limited holds 945,000,000 shares, accounting for 15.60% of the total shares[2]. - Beijing Financial Investment Holdings Limited and its controlled corporations collectively hold 548,409,806 shares, which is 9.05% of the total shares[4]. - Easy Glory Holding Limited beneficially owns 200,400,000 shares, while Advance Finding Investments Limited holds 124,284,000 shares, totaling 324,684,000 shares attributed to 江河創建集團股份有限公司[11]. - The beneficial ownership structure indicates significant control by Beijing Enterprises Group Company Limited over multiple entities holding shares[4]. - Mr. Wang Zheng Chun is deemed to be interested in 35,074,000 shares, held beneficially by his spouse, representing approximately 0.56% of the issued share capital[19]. - Hillfame Holdings Limited holds 64,811,000 shares, fully beneficially owned by Mr. Wang, accounting for about 1.02% of the issued share capital[22]. - No other persons, apart from directors or chief executives, have been notified of interests or short positions in the company's shares as of December 31, 2022[12]. Financial Performance - The Group's loss for the year increased to HK$98,805,000 in 2022, compared to HK$40,234,000 in 2021[52]. - Consolidated revenue for 2022 was approximately HK$166,484,000, representing an 18% decrease compared to 2021[52]. - The Group's annual loss increased to HK$98,805,000 in 2022, compared to a loss of HK$40,234,000 in 2021, with total revenue approximately HK$166,484,000, a decrease of 18% year-on-year[55]. - The cost of sales was approximately HK$119,972,000, reflecting a year-on-year decrease of 23%[135]. - Other income and gains decreased by 44.5% to approximately HK$36,864,000, down from HK$66,447,000 in 2021[135]. - The Group's cash and cash equivalents amounted to approximately HK$420 million, down from HK$470 million in 2021[52]. - The Group's cash and cash equivalents as of December 31, 2022, were approximately HK$193,726,000, down by approximately HK$45,410,000 from HK$239,136,000 in 2021[170]. - Interest-bearing bank and other borrowings were approximately HK$25,747,000 as of December 31, 2022, compared to HK$36,693,000 in 2021[170]. Business Operations and Strategy - The Group continues to focus on its principal businesses while strictly controlling business risks to maintain performance stability[53]. - The Group aims to become a benchmark enterprise in the geriatric care industry in China by actively deploying a comprehensive aging industrial chain[82]. - The Group is focusing on the development of the geriatric care business in the Yangtze River Delta region, emphasizing the integration of medical services and geriatric care[54][82]. - The Group's integrated medical and geriatric care model has been widely recognized and effectively mitigated the impacts of the COVID-19 pandemic, leading to increased customer inquiries and satisfaction[63][82]. - The Group is focusing on stringent cost control and optimizing cost efficiency through prudent capital management and investments in wealth management products, equity, and bonds[110]. - The Group's strategy integrates medical and geriatric care, aiming to create professional and chain-managed geriatric care institutions[86]. - The Group is actively participating in offline exhibitions and brand promotion to prepare for sustainable market development in the furniture industry, anticipating a round of retaliatory purchases[109]. Corporate Governance - The Group acknowledged the importance of good corporate governance and has complied with the code provisions set out in the Corporate Governance Code throughout the year[145]. - The Company has adopted measures to ensure a high standard of corporate governance relevant to its operations[145]. - The Board currently comprises 11 members, including 6 Executive Directors and 5 Independent Non-executive Directors[148]. - The Company has established four Board committees: Audit Committee, Remuneration Committee, Nomination Committee, and Investment and Risk Management Committee, each with defined written terms of reference[190]. - The Audit Committee comprises three members, all of whom are Independent Non-executive Directors, ensuring oversight of financial reporting and compliance[190]. - The Company received annual written confirmations regarding the independence of its Independent Non-executive Directors, confirming their independence[185]. - The Board has ensured compliance with relevant legal and regulatory requirements, including the Corporate Governance Code[187]. Employee and Talent Management - The Group provided generous social security benefits to employees to enhance their sense of belonging and motivation at work[1]. - The Group's overall remuneration system is market-oriented, ensuring competitive salaries to attract and retain high-caliber personnel[1]. - As of December 31, 2022, the Group had approximately 166 employees, with total staff costs amounting to approximately HK$43,382,000, a decrease from HK$46,244,000 in 2021[1]. - The Group has increased its professional talent pool to ensure sustainable business development[86]. - The Company organized internal training courses covering topics such as accounting, finance, risk management, and tax laws during the year[1]. Market Conditions and Future Outlook - The overall economy in China began to recover steadily in the second half of 2022, following the impacts of the COVID-19 pandemic[53]. - Future economic activities are expected to gradually recover as the COVID-19 pandemic is brought under control, although uncertainties remain in the short-term business environment[163]. - The Group is focused on expanding market share and driving innovation amidst a complex and changing environment[163]. - The Group has maintained good relationships with banks to ensure easy access to loans for future growth[170].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於開曼群島註冊成立的有限公司） （股份代號：2 3 8 9 ） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 告 北京健康（控股）有限公司（「本公司」）董事會（「董事會」）宣佈本公司及其附屬公 司（統稱「本集團」）根據香港財務報告準則所編製截至二零二二年十二月三十一 日止年度之綜合全年業績，連同二零二一年之比較數字載列如下： 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 4 166,484 203,776 銷售成本 (119,972) (156,785) ...

Financial Performance - Revenue for the six months ended June 30, 2022, was HK$91,807,000, representing an increase of 15.4% compared to HK$79,619,000 in the same period of 2021[10]. - Gross profit for the same period was HK$25,254,000, up from HK$22,554,000, indicating a growth of 12.0%[10]. - Loss before tax for the period was HK$35,673,000, compared to a loss of HK$18,035,000 in the prior year, reflecting an increase in losses of 97.5%[10]. - Loss for the period amounted to HK$34,387,000, which is significantly higher than the loss of HK$11,445,000 recorded in the previous year, marking an increase of 200.5%[10]. - Total comprehensive loss for the period was HK$127,904,000, compared to HK$17,609,000 in the same period last year, indicating a substantial increase of 726.5%[13]. - Basic and diluted loss per share attributable to ordinary equity holders of the parent was HK(0.54) cents, compared to HK(0.20) cents in the previous year[18]. - Other income and gains, net, decreased to HK$22,851,000 from HK$41,456,000, a decline of 44.8%[10]. - Selling and distribution expenses increased to HK$6,429,000 from HK$5,691,000, reflecting a rise of 13.0%[10]. - Administrative expenses decreased to HK$55,951,000 from HK$63,293,000, a reduction of 11.5%[10]. - The company reported a share of losses from joint ventures amounting to HK$6,788,000, compared to HK$1,689,000 in the previous year, indicating a significant increase in losses of 302.5%[10]. Assets and Liabilities - Total non-current assets decreased from HK$2,087,133,000 as of December 31, 2021, to HK$1,912,330,000 as of June 30, 2022, representing a decline of approximately 8.4%[20]. - Current assets decreased from HK$750,827,000 as of December 31, 2021, to HK$687,059,000 as of June 30, 2022, reflecting a reduction of about 8.5%[20]. - Total current liabilities decreased from HK$246,300,000 as of December 31, 2021, to HK$216,913,000 as of June 30, 2022, indicating a decline of approximately 11.9%[20]. - Net assets decreased from HK$2,496,619,000 as of December 31, 2021, to HK$2,295,443,000 as of June 30, 2022, a decrease of around 8.1%[22]. - Total equity attributable to the owners of the parent decreased from HK$2,293,624,000 as of December 31, 2021, to HK$2,181,038,000 as of June 30, 2022, reflecting a decline of approximately 4.9%[22]. - Cash and cash equivalents increased from HK$239,136,000 as of December 31, 2021, to HK$137,928,000 as of June 30, 2022, showing a decrease of about 42.3%[20]. - The company reported a total of HK$470,146,000 in net current assets as of June 30, 2022, down from HK$504,527,000 as of December 31, 2021, a decline of approximately 6.8%[20]. - Non-controlling interests decreased significantly from HK$202,995,000 as of December 31, 2021, to HK$114,405,000 as of June 30, 2022, a drop of about 43.5%[22]. - Total non-current liabilities decreased from HK$95,041,000 as of December 31, 2021, to HK$87,033,000 as of June 30, 2022, indicating a reduction of approximately 8.4%[22]. Cash Flow and Financing - Cash flows used in operating activities amounted to HK$1,009,000, a significant improvement from HK$55,628,000 used in the previous year, reflecting a reduction in cash outflow[64]. - Net cash flows from investing activities were negative at HK$90,564,000, compared to a positive inflow of HK$6,906,000 in the prior year, primarily due to increased investments and disposals[67]. - The company had cash and cash equivalents of HK$137,928,000 at the end of the period, down from HK$436,231,000 at the end of June 2021, representing a decrease of approximately 68.3%[70]. - New bank loans amounted to HK$37,807,000, while repayments of bank loans were HK$36,255,000, indicating a net increase in bank loans during the period[70]. - The company received bank interest income of HK$444,000, a decrease from HK$2,469,000 in the previous year, reflecting lower interest rates or reduced cash balances[67]. - The company incurred finance costs of HK$602,000, down from HK$949,000 in the previous year, suggesting improved cost management in financing[64]. Revenue Breakdown - Total revenue from contracts with customers for the six months ended June 30, 2022, was approximately HK$91,807,000, representing an increase of 15.5% compared to HK$79,619,000 for the same period in 2021[102]. - Revenue from the sale of goods was HK$88,126,000 for the six months ended June 30, 2022, up from HK$75,662,000 in 2021, indicating a growth of 16.4%[103]. - Revenue from rendering of services decreased slightly to HK$3,681,000 in 2022 from HK$3,957,000 in 2021, reflecting a decline of 7.0%[103]. - The Group's revenue is recognized when control of goods is transferred at a point in time, while service revenue is recognized over time[108]. Accounting Policies and Compliance - The interim condensed consolidated financial information for the six months ended 30 June 2022 has been prepared in accordance with the applicable disclosure requirements of the Listing Rules and Hong Kong Accounting Standard 34[76]. - The accounting policies adopted are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2021, with the adoption of revised Hong Kong Financial Reporting Standards for the current period[80]. - Amendments to HKFRS 3 and HKAS 37 were applied prospectively, clarifying the recognition principles for business combinations and onerous contracts, respectively, with no impact on the financial position or performance of the Group during the period[88]. - The Group has not identified any onerous contracts as of 1 January 2022, indicating no adverse financial implications from the amendments[88]. - The interim financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements[76]. Market and Operational Insights - The company is involved in providing medical care, health care, and geriatric care services and products in the People's Republic of China, indicating a focus on the healthcare sector[73]. - The Group's operating segment information indicates that the majority of revenue is generated from Mainland China, highlighting the importance of this market[96]. - The Group's financial instruments and deferred tax assets are primarily located in Mainland China, which is a key market for the Group[96]. - The Group's financial liabilities were not modified during the reporting period, indicating stability in financial management[94]. - The Group's overall financial performance demonstrates resilience and growth potential in a competitive market environment[102]. Investment and Fair Value - The fair value reserve of financial assets at fair value through other comprehensive income was reported at HK$7,814,000, indicating fluctuations in investment valuations[26]. - The fair value of equity investments designated at fair value through other comprehensive income decreased from HK$323,881,000 as of December 31, 2021, to HK$234,192,000 as of June 30, 2022, a decrease of approximately 27.8%[173]. - Financial assets at fair value through profit or loss increased from HK$253,169,000 as of December 31, 2021, to HK$340,759,000 as of June 30, 2022, an increase of approximately 34.5%[173]. - The total fair value of financial instruments as of June 30, 2022, is HK$234,192,000, with HK$198,879,000 from observable inputs[186]. - The fair values of listed equity and debt investments are based on quoted market prices, ensuring accurate valuation in the financial statements[175]. Shareholder Information - The company did not recommend any payment of interim dividend to shareholders for the six months ended 30 June 2022, consistent with the previous year[9]. - The company has 278,000 share options outstanding as of 30 June 2022, with no movement under the share option scheme during the period[138]. - The exercise of all outstanding share options would result in additional share capital of HK$55,600,000 and share premium of HK$105,060,000[147].

Financial Performance - Revenue for the year ended December 31, 2021, was HK$203,776,000, representing an increase of 36% compared to HK$149,887,000 in 2020[14] - The loss attributable to the owners of the parent for 2021 was HK$39,410,000, a significant improvement from a loss of HK$185,324,000 in 2020[14] - Total assets as of December 31, 2021, amounted to HK$3,890,963,000, up from HK$3,752,718,000 in 2020[15] - Total liabilities decreased to HK$720,950,000 in 2021 from HK$619,673,000 in 2020, indicating improved financial stability[15] - Equity attributable to owners of the parent increased to HK$2,888,193,000 in 2021, compared to HK$2,847,967,000 in 2020[15] - The Group's loss for the year 2021 was significantly reduced to HK$40,234,000, compared to HK$199,989,000 in 2020, while consolidated revenue increased by 36% to approximately HK$203,776,000[18] - As of December 31, 2021, cash and cash equivalents amounted to approximately HK$470 million, slightly down from HK$480 million in 2020, indicating a stable financial position amidst industry challenges[18] - The cost of sales increased by 34% year-on-year to approximately HK$156,785,000, which includes purchases, freight, installation fees, and wage expenses[60] - The overall gross profit margin for the year was 23.1%, a slight increase of 1.2% from 21.9% in the previous year, but still lower than the approximately 30% gross profit margin from the year before[60] - Other income and gains amounted to approximately HK$66,447,000, an increase of 18.7% compared to HK$55,991,000 in 2020[62] - Selling and distribution expenses were approximately HK$13,783,000, representing 6.8% of total sales, down from 13.4% in 2020[62] - Administrative expenses increased by 6.6% to HK$119,095,000 compared to HK$111,770,000 in 2020, mainly due to a one-off maintenance fee incurred during the year[62] - The Group's net current assets reached HK$504,527,000 with a current ratio of 3 times as of December 31, 2021[66] - The Group's bank loans as of December 31, 2021, were secured by properties with carrying amounts of HK$26,363,000 and HK$32,642,000 for investment properties[68] - The Group's exposure to foreign exchange risks was primarily related to investments in joint ventures denominated in CAD and debt investments in US dollars, with no hedging arrangements in place[71] Market Strategy and Growth - The company plans to expand its market presence and invest in new technologies to enhance service offerings in the healthcare sector[17] - New product development initiatives are underway, focusing on innovative healthcare solutions to meet growing market demands[17] - The management is optimistic about future growth, projecting a continued upward trend in revenue and profitability for the upcoming fiscal year[17] - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its service portfolio[17] - A strategic review of operational efficiencies is being conducted to optimize costs and improve overall performance[17] - The Group's strategy focuses on integrated medical and geriatric care, aiming to develop professional and chain-managed geriatric care institutions[24] - The Group plans to expand its geriatric services in Wuxi and Changzhou, increasing bed capacity by 300 and 1,000 respectively in 2022[55] - The Group anticipates no new business investments in 2022, focusing instead on promoting innovation and expanding market share in existing businesses[49] - The Group remains optimistic about the Chinese geriatric market and related businesses, despite facing multiple challenges in 2022[50] Operational Performance - The Group operated five geriatric care institutions with a total of 1,055 beds, achieving an average occupancy rate of 70%, with well-established projects exceeding 90%[24] - The operating revenue from geriatric care services reached RMB32.35 million in 2021, representing a year-on-year increase of 26.2% from RMB25.64 million in 2020[28] - The sales business of medical and geriatric products saw a 36% year-on-year increase in operating revenue to HK$195,194,000, with a contracted but undelivered amount of RMB222 million as of December 31, 2021[21] - The Group achieved "zero infection" among elders and workers in all operating projects during the year, boosting consumer confidence in the brand[25] - The Group has added 10 reserve hospital directors, 30 medical professionals, and 15 various professionals in 2021 to enhance its talent pool for future development[24] Corporate Governance - The Group has complied with the Corporate Governance Code throughout the year ended December 31, 2021[83] - The Group has implemented corporate governance practices relevant to its operations and growth[82] - The Company has established four Board committees, including the Audit Committee, Remuneration Committee, Nomination Committee, and Investment and Risk Management Committee, to oversee specific aspects of its affairs[103] - All members of the Audit Committee are Independent Non-executive Directors, ensuring independence in financial oversight[105] - The Audit Committee is responsible for reviewing the financial statements and reports, considering significant items raised by auditors before submission to the Board[106] - The Company has adopted a Board Diversity Policy to achieve diversity on the Board, considering various aspects such as gender, age, and professional experience[116] - The Company aims to maintain an appropriate mix and balance of skills, knowledge, experience, and diversity of perspectives on the Board[116] - The Board reserves the decision on all major matters, including financial information and significant operational matters[96] Risk Management - The Board confirmed that it is responsible for establishing a risk management and internal control system, which will be reviewed for effectiveness at least once a year[135] - The Audit Committee has reviewed the effectiveness of the risk management and internal control systems covering financial, operational, and compliance controls during the reporting period[136] - The Company has established an internal audit function and engaged professional consultants for risk identification and evaluation, ensuring effective risk management measures are in place[146] - The Company will monitor exchange rate trends closely and apply financial hedging tools to mitigate exchange rate risks associated with its increasing overseas investments[188] Shareholder Relations - The Company emphasizes effective communication with shareholders to enhance investor relations and understanding of business performance[154] - The Company maintains a website for up-to-date information on business operations, financial data, and corporate governance practices[159] - The Company recognizes the importance of shareholder meetings as a forum for dialogue between the Board and shareholders[156] - The Company has a focus on transparency and timely disclosure of information to aid investment decisions[159]

北京健康(控股)有限公司 Beijing Health ( Holdings ) Limited (Formerly known as Beijing Enterprises Medical and Health Industry Group Limited) （前稱北控醫療健康產業集團有限公司） Incorporated in the Cayman Islands with limited liability Stock Code 股份代號 : 2389 於開曼群島註冊成立之有限公司 2021 Interim Report 中 期 報 告 CONTENTS 目錄 Unaudited Interim Financial Information 未經審核中期財務資料 Interim Condensed Consolidated: 中期簡明綜合： 2 Statement of Profit or Loss and Other Comprehensive Income | --- | |---------------------------------| | | | 損益及其他全面收益表 | | Statement ...

Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 Stock Code 股份代號 : 2389 2020 Annual Report 年 報 Contents 目錄 | --- | --- | --- | --- | |-------|-------|-------|-----------------------------------------------| | | | | | | 2 | Corporate Information 公司資料 | 56 | Independent Auditor's Report 獨立核數師報告 | | 4 | Corporate Structure 公司架構 | 63 | Consolidated Statement of Profit or Loss and Other Comprehensive Income 綜合損益及其他全面收益表 | | 5 | Financial Summary 財務摘要 | 66 | Consolidated Statement of Finan ...

上控醫療健康產業集團有限公司 Beijing Enterprises Medical And Heath Industry Group Limited Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 Stock Code 股份代號 : 2389 Interim Report 中 期 報 暗 CONTENTS 目錄 Unaudited Interim Financial Information 未經審核中期財務資料 Interim Condensed Consolidated: 中期簡明綜合： 2 Statement of Profit or Loss and Other Comprehensive Income 損益及其他全面收益表 5 Statement of Financial Position 財務狀況表 7 Statement of Changes in Equity 權益變動表 9 Statement of Cash Flows 現金流量表 12 Notes to Interim Condensed C ...

北控醫療情療產業集團有限公 Beijing Enterprises Medical And Health Industry Group Limited Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 Stock Code 股份代號 : 2389 REALIZE THE DREAM OF HEALTH RESTORATION 讓 健 康 回 歸 Annual Report 2019 年報 CONTENTS 目錄 2 Corporate Information 公司資料 4 Corporate Structure 公司架構 5 Financial Summary 財務摘要 6 Chairman's Statement 主席報告 9 Management Discussion and Analysis 管理層討論與分析 25 Corporate Governance Report 企業管治報告 42 Directors and Senior Management 董事及高級管理層 47 Directors' Repor ...

上控醫療信房產業集團有限公司 Beijing Enterprises Medical and Health Industry Group Limited Incorporated in the Cayman Islands with limited liability 於聞曼群島註冊成立之有限公司 Stock Code 股份代號 : 2389 1111 2 0 Interim Report 中 期 報 告 CONTENTS 目錄 Unaudited Interim Financial Information 未經審核中期財務資料 Interim Condensed Consolidated: 中期簡明綜合： 2 Statement of Profit or Loss and Other Comprehensive Income 損益及其他全面收益表 5 Statement of Financial Position 財務狀況表 7 Statement of Changes in Equity 權益變動表 9 Statement of Cash Flows 現金流量表 12 Notes to Unaudited ...